AVITA Medical, Inc. (RCEL)
NASDAQ: RCEL · Real-Time Price · USD
10.73
-0.03 (-0.28%)
Sep 3, 2026, 2:32 PM EDT - Market open
AVITA Medical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 75.63 | 71.61 | 64.25 | 50.14 | 34.42 | 33.03 | |
Revenue Growth | 1.00% | 11.45% | 28.14% | 45.68% | 4.23% | 12.98% |
Cost of Revenue | 13.95 | 12.79 | 9.09 | 7.78 | 6.04 | 6.1 |
Gross Profit | 61.68 | 58.82 | 55.16 | 42.36 | 28.38 | 26.92 |
Selling, General & Admin | 76.75 | 80.51 | 91.39 | 65.63 | 45.24 | 37.92 |
Research & Development | 20.15 | 20.84 | 20.36 | 20.82 | 13.86 | 15.67 |
Other Operating Expenses | - | - | - | -1.43 | -3.22 | -1.59 |
Operating Expenses | 96.9 | 101.35 | 111.75 | 85.02 | 55.89 | 52 |
Operating Income | -35.22 | -42.53 | -56.59 | -42.66 | -27.51 | -25.08 |
Interest Expense | -7.91 | -8.3 | -5.36 | -1.92 | -0.02 | -0.03 |
Interest & Investment Income | 0.6 | 0.9 | 2.7 | 3.1 | - | - |
Currency Exchange Gain (Loss) | -0.02 | -0.02 | -0.02 | -0.02 | - | - |
Other Non Operating Income (Expenses) | 0.18 | 2.78 | -0.02 | -0.43 | 0.89 | 0.05 |
EBT Excluding Unusual Items | -42.36 | -47.18 | -59.29 | -41.92 | -26.63 | -25.06 |
Gain (Loss) on Sale of Assets | - | - | - | 9.4 | - | - |
Asset Writedown | - | - | - | - | - | -0.04 |
Other Unusual Items | -0.7 | -1.4 | -2.5 | -2.8 | - | - |
Pretax Income | -43.06 | -48.58 | -61.79 | -35.32 | -26.63 | -25.1 |
Income Tax Expense | 0.02 | 0.01 | 0.05 | 0.07 | 0.04 | 0.04 |
Earnings From Continuing Operations | -43.08 | -48.59 | -61.85 | -35.38 | -26.67 | -25.14 |
Net Income | -43.08 | -48.59 | -61.85 | -35.38 | -26.67 | -25.14 |
Net Income to Common | -43.08 | -48.59 | -61.85 | -35.38 | -26.67 | -25.14 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 30 | 28 | 26 | 25 | 25 | 24 |
Shares Outstanding (Diluted) | 30 | 28 | 26 | 25 | 25 | 24 |
Shares Change | 14.29% | 7.64% | 2.18% | 1.32% | 2.64% | 7.42% |
EPS (Basic) | -1.44 | -1.74 | -2.39 | -1.40 | -1.07 | -1.03 |
EPS (Diluted) | -1.44 | -1.74 | -2.39 | -1.40 | -1.07 | -1.03 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -24.61 | -32.2 | -58.11 | -39.39 | -19.54 | -18.52 |
Free Cash Flow Per Share | -0.82 | -1.16 | -2.25 | -1.55 | -0.78 | -0.76 |
Gross Margin | 81.56% | 82.13% | 85.85% | 84.48% | 82.45% | 81.52% |
Operating Margin | -46.56% | -59.40% | -88.08% | -85.07% | -79.91% | -75.93% |
Profit Margin | -56.96% | -67.85% | -96.25% | -70.56% | -77.47% | -76.13% |
Free Cash Flow Margin | -32.54% | -44.97% | -90.44% | -78.56% | -56.77% | -56.09% |
EBITDA | -32.76 | -40.24 | -55.47 | -42.02 | -26.94 | -24.4 |
EBITDA Margin | -43.32% | -56.19% | -86.33% | -83.81% | -78.26% | -73.89% |
D&A For EBITDA | 2.45 | 2.29 | 1.13 | 0.63 | 0.57 | 0.67 |
EBIT | -35.22 | -42.53 | -56.59 | -42.66 | -27.51 | -25.08 |
EBIT Margin | -46.56% | -59.40% | -88.08% | -85.07% | -79.91% | -75.93% |
Revenue as Reported | 75.63 | 71.61 | 64.25 | 50.14 | - | - |
Advertising Expenses | - | 0.49 | 0.54 | 0.4 | 0.22 | - |